- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00625404
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to investigate the safety and effectiveness of a once-daily Truvada® pill (compared with placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through sexual intercourse.
The study population included HIV-antibody-negative women between the ages of 18-35 who were at risk of HIV acquisition through sexual intercourse. Each participant was randomized to take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical placebo.
After enrollment, each participant was followed every four weeks. All participants were followed for an additional eight weeks after study drug was stopped. Incidence rates of HIV infection were compared between the two groups (active drug and placebo) using the intent-to-treat principle.
연구 개요
상세 설명
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to investigate the safety and effectiveness of a once-daily Truvada® pill (compared with placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through sexual intercourse.
The study population included HIV-antibody-negative women between the ages of 18-35 who were at risk of HIV acquisition through sexual intercourse. Each participant was randomized to take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical placebo. All participants received risk reduction counseling and condoms. Women had to be using a study-approved effective non-barrier contraceptive method at the time of enrollment and were asked to do so for the whole period they were on study drug. They received contraceptive counseling throughout the study. Any diagnosed, treatable sexually transmitted infection was treated free of charge.
After enrollment, each participant was followed every four weeks. All participants were followed for an additional eight weeks after study drug was stopped. Participants at risk for Hepatitis B Virus (HBV) flare were followed every four weeks for 12 weeks after stopping study product. Participants who acquired HIV infection during the study stopped taking the study drug at the time of HIV diagnosis, and will be followed for 52 weeks post diagnosis and were referred for care and treatment. Participants who became pregnant stopped taking the study drug but continued follow-up visits. Incidence rates of HIV infection were compared between the two groups (active drug and placebo) using the intent-to-treat principle.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Willing and able (see criterion 2) to provide written informed consent to be screened for and to participate in the trial
- Able to answer a percentage of informed consent screening (75%) and enrollment (100%) comprehension quiz questions correctly
- Between 18-35 years old, inclusive
- At higher risk of becoming HIV infected
- Have a final negative result according to the site-specific screening HIV testing algorithm and a final negative result at enrollment according to the study HIV testing algorithm
Willing to participate in all aspects of the study and to comply with study procedures, for up to 60 weeks, including:
- Be randomized
- Use study product as directed
- Adhere to follow-up schedule and willing to be contacted by site staff between study visits (by phone and/or in person)
- Use a study-approved effective non-barrier method of contraception for the duration of the study
- Take study product, as evidenced by swallowing a vitamin tablet that is similar in size to the study product at enrollment
- Provide contact information and agrees to some form of contact method throughout the study
- Not intending to relocate out of the area for the duration of the study participation and does not have a job or other obligations that may require long absences from the area ( > 1 month at a time)
- In general good health and have no condition (social or medical) which, in the opinion of the Site Investigator, would make study participation unsafe or complicate data interpretation
- Not pregnant or breastfeeding, and does not anticipate a desire for pregnancy during the 52 weeks of on-product participation
Medically eligible at screening including:
- Adequate renal function (serum creatinine ≤ upper limit of normal (ULN) of local range and creatinine clearance ≥ 60ml/min estimated by the Cockcroft-Gault Creatinine Clearance Formula
- Adequate hepatic function (hepatic transaminases ALT and AST < 2x ULN [according to local normal ranges])
- HBsAg negative
- Serum phosphorus levels above the lower limit of the local normal range (according to local normal ranges - grade 3 & 4 hypophosphatemia will be excluded even if within normal local ranges)
- Not received or receiving an experimental HIV vaccine, participating in another HIV prevention study or participating in any other clinical trial with a biomedical intervention
- No clinical signs of liver disease (e.g., ascites, spider angiomata, hepatomegaly, jaundice)
- No definite evidence of glycosuria or proteinuria (i.e., no repeated positive [ ≥ + 1 ] urine dipstick). If a urine dipstick is positive for either glucose and/or protein at the first test, a second urine sample will be tested.
- No history of pathological bone fractures
- No history of adverse reaction to latex
- Not taking any of the following medications: nephrotoxic agents; aminoglycoside antibiotics (including gentamicin); intravenous (IV) amphotericin B; cidofovir; cisplatin; foscarnet; IV pentamidine; oral or IV vancomycin; oral or IV gancyclovir; other agents with significant nephrotoxic potential; drugs that slow renal excretion; probenecid; immune system modulators; systemic chemotherapeutic agents (i.e. cancer treatment medications); systemic corticosteroids; interleukin-2 (IL-2); immunomodulators; interferon (alpha, beta, or gamma); other antiretrovirals (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Truvada Arm
Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
|
Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
다른 이름들:
|
위약 비교기: Placebo Arm
Daily single oral tablet of Placebo.
Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
|
Daily single oral tablet of Placebo.
Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
HIV Infection
기간: Cumulative HIV infection between enrollment and 52 weeks
|
HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens.
|
Cumulative HIV infection between enrollment and 52 weeks
|
Confirmed Grade 2 or Higher Serum Creatinine Toxicity
기간: cumulative toxicity through 52 weeks of product use and 4 weeks post product
|
Repeat specimens were collected to confirm chemistry toxicities.
Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal
|
cumulative toxicity through 52 weeks of product use and 4 weeks post product
|
Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration
기간: 10-26 months per site
|
The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration.
|
10-26 months per site
|
Confirmed Grade 3 or Higher Reduction in Phosphorus
기간: Through 52 weeks on product and 4 weeks post-product
|
Repeat specimens were collected to confirm chemistry toxicities.
Grade 3 phosphorus reduction was defined as ≤2.4mg/dL
|
Through 52 weeks on product and 4 weeks post-product
|
Confirmed Grade 3 or Higher ALT Elevation
기간: Through 52 weeks on product and 4 weeks post-product
|
Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal
|
Through 52 weeks on product and 4 weeks post-product
|
Confirmed Grade 3 or Higher AST Elevation
기간: Through 52 weeks on product and 4 weeks post-product
|
Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal
|
Through 52 weeks on product and 4 weeks post-product
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Plasma HIV RNA Level (HIV-1 Viral Load)
기간: up to 16 weeks
|
Viral load at the time of HIV detection, HIV conversion and through 16 weeks
|
up to 16 weeks
|
CD4+ T-cell Count
기간: Up to 16 weeks
|
CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks
|
Up to 16 weeks
|
FTC and/or Tenofovir Resistance
기간: up to 52 weeks
|
Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected). participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time. |
up to 52 weeks
|
Pregnancy Complications
기간: up to 60 weeks
|
Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications
|
up to 60 weeks
|
Pill Counts and Participant Report of Adherence to Once-daily Pill Taking
기간: Up to 52 weeks
|
Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts
|
Up to 52 weeks
|
Participant Report of Change in Number of Sexual Partners
기간: Up to 52 weeks
|
Difference in mean number of reported sexual partners between final study visit and enrollment visit
|
Up to 52 weeks
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Lut Van Damme, MD, MS, PhD, FHI 360
- 수석 연구원: Amy Corneli, PhD, MPH, FHI 360
- 연구 책임자: Jennifer Deese, MPH, FHI 360
간행물 및 유용한 링크
일반 간행물
- Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.
- Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D, Van Damme L. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol. 2014 Dec 24;15:77. doi: 10.1186/2050-6511-15-77.
- Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015 Jan 28;29(3):331-7. doi: 10.1097/QAD.0000000000000556.
- Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L; FEM-PrEP Study Group. Sino-implant (II)(R) continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception. 2015 Mar;91(3):248-52. doi: 10.1016/j.contraception.2014.10.008. Epub 2014 Oct 22.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 10015 (기타 식별자: Fred Hutch/University of Washington Cancer Consortium)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
CDC FoundationGilead Sciences알려지지 않은
-
University of WashingtonNational Institute of Mental Health (NIMH)모병
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Erasmus Medical Center모집하지 않고 적극적으로
Truvada에 대한 임상 시험
-
HIV Prevention Trials NetworkGilead Sciences모집하지 않고 적극적으로
-
FHI 360Gilead Sciences; University of North Carolina, Chapel Hill; Family Health Options Kenya; Institute... 그리고 다른 협력자들빼는
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...완전한
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA); Asociación Civil Impacta Salud y Educación, Peru; Asociación Civil Via Libre, Peru 그리고 다른 협력자들완전한
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Gilead Sciences완전한